Semaglutide and Teduglutide Reduce Intestinal Injury
New research shows that activating specific hormone receptors may help protect the gut from damage induced by T cells.
Updated on Oct. 22, 2026 in Diabetes
Live Poll
Do you trust that pharmaceutical treatments for gut inflammation offer more benefit than risk?
Scientists have found that the drugs semaglutide and teduglutide can reduce T cell-induced intestinal injury in mice. The study, published in October 2026, highlights how activating GLP-1 and GLP-2 receptors can help mitigate gut damage.
Why it matters
The study suggests that GLP hormone receptors play a protective role in the gut, potentially offering new therapeutic avenues for preventing intestinal injury. This discovery helps researchers better understand how these hormonal pathways regulate immune responses and tissue health.
Researchers administered semaglutide at 2.5 μg/kg and teduglutide at 40 μg/kg to male mice aged 12 to 16 weeks to observe protective effects. Immune-cell experiments also utilized a 10 μg/kg dose of semaglutide.
The players
Cell Reports Medicine
This is a peer-reviewed scientific journal that focuses on clinical and translational research.
The details
By using 16S ribosomal RNA sequencing, the team characterized microbiome shifts and confirmed that mice lacking intestinal proglucagon were more vulnerable to injury. Treatment with these drugs lowered blood cytokine concentrations and inhibited neutrophil infiltration in the gut.
Timeline
October 2026: The study was published in Cell Reports Medicine.
The Big Picture
This study extends current research into the GLP-1 receptor agonist drug class by demonstrating potential non-metabolic benefits for gut health. It shifts the focus from purely weight-related outcomes to the protective role of hormonal signaling in the intestines.
While this research offers insight into gut health, it remains in the preclinical stage and does not impact current treatment options for patients. Future studies will be required to determine if these findings can be safely translated into human therapies.
The takeaway
This research highlights the hidden protective capabilities of GLP-1 and GLP-2 receptors beyond their well-known metabolic functions. Understanding these pathways may eventually lead to new strategies for managing intestinal inflammation and injury.
Further reading
Learn more about the latest developments in the field by visiting our Diabetes section.
More information
Read the full journal article on cell reports00532-X).
Source note: This article includes information reported by News-Medical.
Live Poll
Do you trust that pharmaceutical treatments for gut inflammation offer more benefit than risk?
